Analysts Issue Forecasts for CADL FY2026 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Investment analysts at Brookline Capital Markets issued their FY2026 EPS estimates for shares of Candel Therapeutics in a research note issued on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will earn ($1.28) per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.30) per share.

Several other research firms have also issued reports on CADL. HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Candel Therapeutics in a research note on Thursday, August 13th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Bank of America boosted their target price on shares of Candel Therapeutics from $9.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Stifel Nicolaus initiated coverage on Candel Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $22.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $19.29.

Candel Therapeutics Price Performance

Shares of Candel Therapeutics stock opened at $12.35 on Friday. The firm has a market cap of $945.02 million, a P/E ratio of -8.76 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. Candel Therapeutics has a twelve month low of $4.35 and a twelve month high of $13.82. The firm’s 50-day simple moving average is $10.01 and its 200-day simple moving average is $7.60.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.28).

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CADL. Janus Henderson Group PLC acquired a new stake in Candel Therapeutics in the 1st quarter valued at approximately $845,000. Halter Ferguson Financial Inc. boosted its holdings in Candel Therapeutics by 20.9% during the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after purchasing an additional 155,996 shares during the last quarter. Walleye Capital LLC bought a new position in Candel Therapeutics in the second quarter valued at $419,000. Renaissance Technologies LLC acquired a new stake in Candel Therapeutics in the 1st quarter valued at $63,000. Finally, AlphaCentric Advisors LLC bought a new stake in Candel Therapeutics during the 1st quarter worth about $178,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider owned 77,362 shares of the company’s stock, valued at approximately $778,261.72. This trade represents a 23.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer directly owned 76,865 shares in the company, valued at approximately $922,380. This represents a 8.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 37,447 shares of company stock valued at $390,017. 14.30% of the stock is owned by corporate insiders.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.